We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients.
READ FULL ARTICLE
From New England Journal of Medicine
TAS-102 Provides Survival Benefit in Refractory Colorectal Cancer
the Cancer Therapy Advisor take:
In patients with refractory colorectal cancer, TAS-102 was associated with a significant improvement in overall survival compared with placebo, a study published in the New England Journal of Medicine has shown.
For the double-blind study, researchers enrolled 800 patients with refractory colorectal cancer and randomly assigned them 2:1 to receive TAS-102 or placebo.
Results showed that the median overall survival was 5.3 months and 7.1 months in the placebo and TAS-102 groups, respectively (HR for death = 0.68; 95% CI: 0.58-0.81; P < 0.001).
In regard to safety, the most common adverse events associated with TAS-102 were neutropenia, leukopenia, and febrile neutropenia. One patient died as a result of TAS-102 treatment. Median time to worsening performance status was also 1.7 months longer in the TAS-102 arm than the placebo arm (HR = 0.66; 95% CI: 0.56-0.78; P < 0.001).
TAS-102 is an oral agent that combines trifluridine and tipiracil hydrochloride. Previous studies conducted mostly in Japan that it was effective in the treatment of patients with refractory colorectal cancer.
